POLYMYXIN B SULFATE

Post-LOE

polymyxin b sulfate

Gland Pharma

ANDAINJECTIONINJECTABLE

Approved

Apr 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

POLYMYXIN B SULFATE (polymyxin b sulfate) by Gland Pharma is clinical pharmacology polymyxin b sulfate has a bactericidal action against almost all gram-negative bacilli except the proteus group. Approved for serious infections caused by susceptible strains of the following organisms, less potentially toxic drugs are ineffective, contraindicated: h. First approved in 2016.

Drug data last refreshed 22h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the Proteus group. Polymyxins increase the permeability of the bacterial cell membrane leading to death of the cell. All gram-positive bacteria, fungi, and gram-negative cocci are…

Indications (3)

serious infections caused by susceptible strains of the following organisms

Worked on POLYMYXIN B SULFATE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.